Methods for Diagnostic & Therapeutic Studies | Lymphomas & Myelomas
Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL)
Fabio PS Santos, Susan O'Brien, Deborah A. Thomas, Jorge Cortes, Stefan Faderl, Jeffrey L Jorgensen, Rebecca Garris, Charles Koller, Partow Kebriaei, Alessandra Ferrajoli, Hagop Kantarjian, Farhad Ravandi*
*Corresponding author: Farhad Ravandi
Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
F1000Posters 2010, 1: 188 (poster) [ENGLISH]
Poster [342.20 KB]
Presented at
51st American Society of Hematology Annual Meeting 2009,
5 - 8 Dec 2009, 984
Although the treatment of patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) has evolved with the introduction of tyrosine kinase inhibitors (TKI), there is still a high incidence of relapse. We sought to determine the prognostic impact of the expression of two markers that have been associated with adverse outcomes (CD20 and CD25) in patients.
Our retrospective data review revealed that in patients with Ph+-ALL treated with regimens combining conventional chemotherapy and TKI, expression of CD20 may be associated with better survival outcomes, but CD25 did not influence survival.
Cortes: Novartis Research Funding; Bristol Myers Squibb (BMS) Research Funding. Kantarjian: Novartis Research Funding; BMS Research Funding.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
